MARKET

VTGN

VTGN

VistaGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.140
+0.010
+0.47%
After Hours: 1.970 -0.17 -7.94% 16:23 05/14 EDT
OPEN
2.160
PREV CLOSE
2.130
HIGH
2.210
LOW
2.120
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
3.180
52 WEEK LOW
0.3500
MARKET CAP
303.23M
P/E (TTM)
-7.9910
1D
5D
1M
3M
1Y
5Y
VistaGen names new chief commercial officer
VistaGen (VTGN) has named Ann Cunningham as its news chief commercial officer.She has been serving on the company's board since January 2019.Prior to her new role, her most recent positions
Seekingalpha · 05/04 12:24
VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer
Ann Cunningham has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing, and global life cycle product management expertise for many successful branded product campaigns for large pharmaceutical companiesSOUTH S...
GlobeNewswire · 05/04 12:00
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 04/28 16:53
BioMedNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Board Appointment of Dr. Joanne Curley
Apr 27, 2021 (Investor Brand Network via COMTEX) -- VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the...
Investor Brand Network · 04/27 18:07
Novel Anxiety and Depression Approach by VistaGen Therapeutics
The COVID-19 pandemic has exacerbated mental health issues and is triggering new conditions for people already suffering from mental illnesses and substance abuse. 
Benzinga · 04/27 13:33
BRIEF-Vistagen Therapeutics Announces Appointment Of Joanne Curley To Its Board Of Directors
reuters.com · 04/27 12:14
VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors
SOUTH SAN FRANCISCO, Apr 27, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc....
GlobeNewswire · 04/27 12:01
BioMedNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines
Mar 22, 2021 (Investor Brand Network via COMTEX) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines...
Investor Brand Network · 03/22 17:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTGN. Analyze the recent business situations of VistaGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTGN stock price target is 5.67 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 61
Institutional Holdings: 67.50M
% Owned: 47.63%
Shares Outstanding: 141.69M
TypeInstitutionsShares
Increased
8
2.29M
New
28
61.90M
Decreased
4
91.67K
Sold Out
5
233.90K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.15%
Key Executives
President/Chief Scientific Officer/Director
H. Snodgrass
Chairman/Independent Director
Jon Saxe
President/Founder/Chief Scientific Officer/Director
H. Ralph Snodgrass
Chief Executive Officer/Director
Shawn Singh
Chief Financial Officer/Vice President/Secretary
Jerrold Dotson
Senior Vice President
Mark Ginski
Vice President
Mark McPartland
Vice President
Louis Monti-Bloch
Other/Director
Ann Cunningham
Other
Mark Smith
Independent Director
Joanne Curley
Independent Director
Jerry Gin
Independent Director
Brian Underdown
No Data
  • All
  • Financials
  • Insiders
More
About VTGN
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.